<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99097">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01852058</url>
  </required_header>
  <id_info>
    <org_study_id>191622-121</org_study_id>
    <secondary_id>2012-004898-30</secondary_id>
    <nct_id>NCT01852058</nct_id>
  </id_info>
  <brief_title>A Long-Term Extension Study of OnabotulinumtoxinA for Urinary Incontinence Due to Neurogenic Detrusor Overactivity</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the long-term safety and efficacy of onabotulinumtoxinA for the
      treatment of urinary incontinence due to neurogenic detrusor overactivity in patients who
      successfully completed Study 191622-120.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline in Daily Average Frequency of Daytime Urinary Incontinence Episodes</measure>
    <time_frame>Baseline, 60 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Average Urine Volume at First Morning Catheterization</measure>
    <time_frame>Baseline, 60 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Night Time Urinary Incontinence</measure>
    <time_frame>60 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Patient Request for Retreatment</measure>
    <time_frame>48 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Patient Qualification for Retreatment</measure>
    <time_frame>48 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA Dose A injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA Dose B injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA Dose C injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OnabotulinumtoxinA</intervention_name>
    <description>OnabotulinumtoxinA injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.</description>
    <arm_group_label>OnabotulinumtoxinA Dose A</arm_group_label>
    <arm_group_label>OnabotulinumtoxinA Dose B</arm_group_label>
    <arm_group_label>OnabotulinumtoxinA Dose C</arm_group_label>
    <other_name>BOTOX®</other_name>
    <other_name>botulinum toxin A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Successfully completed participation in Study 191622-120

          -  Aged ≥ 8 years to ≤ 17 years at the time of entry into Study 191622-120

          -  Regularly using clean intermittent catheterization to empty the bladder

        Exclusion Criteria:

          -  Myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis

          -  Current or planned use of a baclofen pump

          -  Current or planned use of an electrostimulation/neuromodulation device for urinary
             incontinence

          -  Use of an indwelling catheter for urinary incontinence instead of using clean
             intermittent catheterization to empty the bladder

          -  Previous or current use of botulinum toxin therapy of any serotype for any urological
             condition, or treatment with botulinum toxin of any serotype for any other condition
             since entering study 191622-120
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allergan Inc.</last_name>
    <email>clinicaltrials@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com</url>
    <description>More information</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 16, 2014</lastchanged_date>
  <firstreceived_date>May 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Incontinence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
